This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Immune Pharmaceuticals Ltd.

Drug Names(s): HD-O

Description: HD-O is an orally available formulation of histamine. Research has shown that oxygen free radicals released by certain immune cells can suppress the immune system and damage normal tissue, a process commonly referred to as oxidative stress. Oxidative stress, implicated in numerous diseases, is most pronounced in the liver and can damage or destroy liver tissue in patients with hepatitis and other chronic liver diseases. Histamine has been shown in preclinical testing to prevent the production and release of oxygen free radicals, thereby reducing oxidative stress. Accordingly, treatment with histamine has the potential to prevent or reverse damage induced by oxidative stress, thereby protecting critical cells and tissues, including the liver.

Deal Structure: EpiCept and Immune
In November 2012, Immune Pharmaceuticals and EpiCept announced that they have entered into a definitive merger agreement. The combined company is to be named Immune Pharmaceuticals. In August 2013, Immune announced the completion of the merger of Immune Pharmaceuticals and EpiCept.

HD-O News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug